Cargando…
Machine Learning Use for Prognostic Purposes in Multiple Sclerosis
The course of multiple sclerosis begins with a relapsing-remitting phase, which evolves into a secondarily progressive form over an extremely variable period, depending on many factors, each with a subtle influence. To date, no prognostic factors or risk score have been validated to predict disease...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914671/ https://www.ncbi.nlm.nih.gov/pubmed/33562572 http://dx.doi.org/10.3390/life11020122 |
_version_ | 1783657057978679296 |
---|---|
author | Seccia, Ruggiero Romano, Silvia Salvetti, Marco Crisanti, Andrea Palagi, Laura Grassi, Francesca |
author_facet | Seccia, Ruggiero Romano, Silvia Salvetti, Marco Crisanti, Andrea Palagi, Laura Grassi, Francesca |
author_sort | Seccia, Ruggiero |
collection | PubMed |
description | The course of multiple sclerosis begins with a relapsing-remitting phase, which evolves into a secondarily progressive form over an extremely variable period, depending on many factors, each with a subtle influence. To date, no prognostic factors or risk score have been validated to predict disease course in single individuals. This is increasingly frustrating, since several treatments can prevent relapses and slow progression, even for a long time, although the possible adverse effects are relevant, in particular for the more effective drugs. An early prediction of disease course would allow differentiation of the treatment based on the expected aggressiveness of the disease, reserving high-impact therapies for patients at greater risk. To increase prognostic capacity, approaches based on machine learning (ML) algorithms are being attempted, given the failure of other approaches. Here we review recent studies that have used clinical data, alone or with other types of data, to derive prognostic models. Several algorithms that have been used and compared are described. Although no study has proposed a clinically usable model, knowledge is building up and in the future strong tools are likely to emerge. |
format | Online Article Text |
id | pubmed-7914671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79146712021-03-01 Machine Learning Use for Prognostic Purposes in Multiple Sclerosis Seccia, Ruggiero Romano, Silvia Salvetti, Marco Crisanti, Andrea Palagi, Laura Grassi, Francesca Life (Basel) Review The course of multiple sclerosis begins with a relapsing-remitting phase, which evolves into a secondarily progressive form over an extremely variable period, depending on many factors, each with a subtle influence. To date, no prognostic factors or risk score have been validated to predict disease course in single individuals. This is increasingly frustrating, since several treatments can prevent relapses and slow progression, even for a long time, although the possible adverse effects are relevant, in particular for the more effective drugs. An early prediction of disease course would allow differentiation of the treatment based on the expected aggressiveness of the disease, reserving high-impact therapies for patients at greater risk. To increase prognostic capacity, approaches based on machine learning (ML) algorithms are being attempted, given the failure of other approaches. Here we review recent studies that have used clinical data, alone or with other types of data, to derive prognostic models. Several algorithms that have been used and compared are described. Although no study has proposed a clinically usable model, knowledge is building up and in the future strong tools are likely to emerge. MDPI 2021-02-05 /pmc/articles/PMC7914671/ /pubmed/33562572 http://dx.doi.org/10.3390/life11020122 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Seccia, Ruggiero Romano, Silvia Salvetti, Marco Crisanti, Andrea Palagi, Laura Grassi, Francesca Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title | Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title_full | Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title_fullStr | Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title_full_unstemmed | Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title_short | Machine Learning Use for Prognostic Purposes in Multiple Sclerosis |
title_sort | machine learning use for prognostic purposes in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914671/ https://www.ncbi.nlm.nih.gov/pubmed/33562572 http://dx.doi.org/10.3390/life11020122 |
work_keys_str_mv | AT secciaruggiero machinelearninguseforprognosticpurposesinmultiplesclerosis AT romanosilvia machinelearninguseforprognosticpurposesinmultiplesclerosis AT salvettimarco machinelearninguseforprognosticpurposesinmultiplesclerosis AT crisantiandrea machinelearninguseforprognosticpurposesinmultiplesclerosis AT palagilaura machinelearninguseforprognosticpurposesinmultiplesclerosis AT grassifrancesca machinelearninguseforprognosticpurposesinmultiplesclerosis |